**TRANSMITTAL
FORM***(to be used for all correspondence after initial filing)*

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>	Application Number	10/673,438
	Filing Date	September 30, 2003
	First Named Inventor	Jon Rowley et al.
	Art Unit	1651
	Examiner Name	Unassigned
Total Number of Pages in This Submission	Attorney Docket Number	020187.0239PTUS

ENCLOSURES (check all that apply)

- ☐ Fee Transmittal Form
 - ☐ Fee Attached
- ☐ Amendment / Reply
 - ☐ After Final
 - ☐ Affidavits/declaration(s)
- ☐ Extension of Time Request
- ☐ Express Abandonment Request
- ☒ Information Disclosure Statement
- ☐ Certified Copy of Priority Document(s)
- ☐ Response to Missing Parts/Incomplete Application
 - ☐ Response to Missing Parts under 37 CFR 1.52 or 1.53

- ☐ Drawing(s)
- ☐ Licensing-related Papers
- ☐ Petition
- ☐ Petition to Convert to a Provisional Application
- ☐ Power of Attorney, Revocation Change of Correspondence Address
- ☐ Terminal Disclaimer
- ☐ Request for Refund
- ☐ CD, Number of CD(s) _____

- ☐ After Allowance Communication to Group
- ☐ Appeal Communication to Board of Appeals and Interferences
- ☐ Appeal Communication to Group (Appeal Notice, Brief, Reply Brief).
- ☐ Proprietary Information
- ☐ Status Letter
- ☒ Other Enclosure(s)
(please identify below):
7 pages of SB08 with 89 references

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Laura Nammo, Reg. No. 42,024
Signature	<i>Laura Nammo</i>
Date	<i>February 20, 2004</i>

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name			
Signature		Date	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Jon Rowley et al.

Confirmation No.: 2613

Application No. : 10/673,438

Group Art Unit: 1651

Filed : September 30, 2003

Examiner: Not yet assigned

For : PROGRAMMABLE SCAFFOLD AND METHODS FOR MAKING AND
USING THE SAME

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 (b)(3)

Honorable Commissioner of Patents
Washington, D.C. 20231

Sir:

In accordance with 37 C.F.R. § 1.56, the attention of the Patent and Trademark Office is directed to the 89 cited references listed on the attached PTO/SB/08a and b. No representation is made or intended that more relevant information does not exist or that the order of presentation of the information in any way reflects its relative pertinence. Copies of the references are being submitted herewith.

Applicant's respectfully request that each of the cited references be expressly considered during the prosecution of this application and that the cited references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

It is believed that this Information Disclosure Statement is being filed before the mailing of a first Office Action on the merits. Thus, no certification or fee would be required.

Please credit or debit Deposit Account No. 50-2228 as needed to ensure consideration of the disclosed information.


Respectfully submitted,

Date: February 20, 2004

By: Laura Nammo

Laura Nammo
Registration No. 42,024

Patton Boggs, LLP
8484 Westpark Drive
9th Floor
McLean, VA 22102
Telephone (703) 744-8029
Facsimile (703) 744-8091



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 7

Complete if Known

Application Number	10/673,438
Filing Date	September 30, 2003
First Named Inventor	Jon Rowley et al.
Art Unit	1651
Examiner Name	Unassigned
Attorney Docket Number	020187.239PTUS

NON PATENT LITERATURE DOCUMENTS


Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	ALSBERG E, et al., "Cell-interactive Alginate Hydrogels for Bone Tissue Engineering," J. Dent. Res. 80(11):2025-9. November 2001	
	2	ALSBERG E, et al., "Engineering Growing Tissues", Proc. Natl. Acad. Sci. U. S. A. 99(19):12025-30. September 2002.	
	3	BALGUDE A, et al., "Agarose Gel Stiffness Determines Rate of DRG Neurite Extension in 3D Cultures," Biomaterials. 22(10):1077-84(2001).	
	4	BELLAMKONDA R, et al., "Hydrogel-based Three-Dimensional Matrix for Neural Cells," J. Biomed. Mater. Res. 29(5):663-71(1995).	
	5	BHATIA S et al., "Tissue Engineering at the Micro-scale," Biomed. Microdevices. 2(2):131-44(March 1999).	
	6	BOTTARO D, et al., "Molecular Signaling in Bioengineered Tissue Microenvironments," Ann. N.Y. Acad. Sci. 961:143-53(2002).	
	7	BRYANT S, et al., "Controlling the Spatial Distribution of ECM Components in Degradable PEG Hydrogels for Tissue Engineering Cartilage," J. Biomed. Mater. Res. 64A(1):70-9(January 2003).	
	8	BLUNK T, et al., "Differential Effects of Growth Factors on Tissue-Engineered Cartilage," Tissue Eng. 8(1): 73-84(2002).	
	9	CHANG S, et al., "Injection Molding of Chondrocyte/Alginate Constructs in the Shape of Facial Implants," J. of Biomed. Mater. Res. 55(4): 503-11(June 2001).	
	10	CHARLES K, et al., "Storage and Microencapsulation of Islets for Transplantation," Cell Transplant. 9(1):33-8(January/February 2000).	
	11	CUKIERMAN E, et al., "Cell Interactions with Three-Dimensional Matrices," Curr. Opin. Cell Biol. 14:633-39(2002).	
	12	DAGALAKIS N, et al., "Design of an Artificial Skin. Part III. Control of Pore Structure," J Biomed. Mater. Res. 14(4):511-28(July 1980).	
	13	DAR A, et al. "Optimization of Cardiac Cell Seeding and Distribution in 3D Porous Alginate Scaffolds," Biotechnol. Bioeng. 80(3):305-12(November 2002).	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number


INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/673,438		
		Filing Date	September 30, 2003		
		First Named Inventor	Jon Rowley et al.		
		Art Unit	1651		
		Examiner Name	Unassigned		
Sheet	2	of	7	Attorney Docket Number	020187.0239PTUS

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	14	DIMILLA P, et al., "Maximal Migration of Human Smooth Muscle Cells on Fibronectin and Type IV Collagen Occurs at an Intermediate Attachment Strength," J. Cell. Biol. 122(3):729-37(August 1993).	
	15	DRUMHELLER P, et al., "Polymer Networks with Grafted Cell Adhesion Peptides for Highly Biospecific Cell Adhesive Substrates," Anal. Biochem. 222:380-88(1994).	
	16	EISELT P, et al., "Porous Carriers for Biomedical Applications based on Alginate Hydrogels," Biomaterials. 21(19):1921-7(2000).	
	17	ELISSEFF J, et al., "Controlled-Release of IGF-I and TGF-β1 in a Photopolymerizing Hydrogel for Cartilage Tissue Engineering," J. Orthop. Res. 19(6):1098-104(2001).	
	18	GARFINKEL M, et al., "Optimization of the Microencapsulated Islet for Transplantation," J. Surg. Res. 76(1):7-10(1998).	
	19	GRIFFITH L, et al., "Tissue Engineering--Current Challenges and Expanding Opportunities," Science. 295(5557):1009-14(February 2002).	
	20	GLICKLIS R, et al., "Hepatocyte Behavior within Three-dimensional Porous Alginate Scaffolds," Biotechnol. Bioeng. 67(3):344-53(February 2000).	
	21	HALBERSTADT C, et al., "A Hydrogel Material for Plastic and Reconstructive Applications Injected into the Subcutaneous Space of a Sheep," Tissue Eng. 8(2):309-19(2002).	
	22	HAY E., Cell Biology of Extracellular Matrix, 2nd edition, Plenum Press, 1991.	
	23	HERN D, et al., "Incorporation of Adhesion Peptides into Nonadhesive Hydrogels Useful for Tissue Resurfacing," J. Biomed. Mater. Res. 39(2):266-76(1998).	
	24	HOBBS H, et al., "Prevention of Morphological Changes in Alginate Microcapsules for Islet Xenotransplantation," J. Investig. Med. 49(6):572-5(November 2001).	
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO:** Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 3 of 7

Complete if Known

Application Number	10/673,438
Filing Date	September 30, 2003
First Named Inventor	Jon Rowley et al.
Art Unit	1651
Examiner Name	Unassigned
Attorney Docket Number	020187.0239PTUS

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	25	HUBBELL J., "Biomaterials in Tissue Engineering," Biotechnology (N.Y.) 13(6):565-76(June 1995).	
	26	HUBBELL J, et al., "Surface-Grafted Cell-Binding Peptides in Tissue Engineering of the Vascular Graft," Ann N.Y. Acad. Sci. 665:253-8(October 1992).	
	27	INGBER D., "Control of Capillary Growth and Differentiation by Extracellular Matrix. Use of a Tensegrity (Tensional Integrity) Mechanism for Signal Processing," Chest 99(3 Suppl):34S-40S(1991).	
	28	INGBER D, et al., "Mechanochemical Switching Between Growth and Differentiation During Fibroblast Growth Factor-Stimulated Angiogenesis in vitro: Role of Extracellular Matrix," J. Cell. Biol. 109(1):317-30(July 1989).	
	29	ITO Y, et al., "Enhancement of Cell Growth on Growth Factor-Immobilized Polymer Film," Biomaterials 12(5):449-53(July 1991).	
	30	ITO Y, et al., "Enhancement of the Mitogenic Effect by Artificial Juxtacrine Stimulation using Immobilized EGF," J. Biochem. (Tokyo), 121(3):514-20(March 1997).	
	31	KENDALL W, et al., "Effect of Bead Swelling on the Durability of Polylysine Alginate Microcapsules," Curr. Surg. 57(6):636-37(November/December 2000).	
	32	KIM B, et al., "Development of Biocompatible Synthetic Extracellular Matrices for Tissue Engineering," Trends in Biotechnology 16(5):224-30(May 1998).	
	33	KIM B, et al., "Engineering Smooth Muscle Tissue with a Predefined Structure," J. of Biomed. Mater. Res. 41(2):322-32(August 1998).	
	34	KIM B, et al., "Scaffolds for Engineering Smooth Muscle Under Cyclic Mechanical Strain Conditions," Journal of Biomechanical Engineering 122(3):210-15(June 2000).	
	35	KIM B, et al., "Cyclic Mechanical Strain Regulates the Development of Engineered Smooth Muscle Tissue," Nature Biotechnology 17(10):979-83(October 1999).	
	36	KIM S, et al., "Three-Dimensional Porous Collagen/Chitosan Complex Sponge for Tissue Engineering," Fibers and Polymers, Vol. 2, No. 2, pages 64-70(2001).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 4 of 7

Complete if Known


Application Number	10/673,438
Filing Date	September 30, 2003
First Named Inventor	Jon Rowley et al.
Art Unit	1651
Examiner Name	Unassigned
Attorney Docket Number	020187.0239PTUS

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	37	KIM W, et al., "Cartilage Engineered in Predetermined Shapes Employing Cell Transplantation on Synthetic Biodegradable Polymers," Plastic and Reconstructive Surgery 94(2):233-37(August 1994).	
	38	EHRENFREUND-KLEINMAN T, et al., "Synthesis and Biodegradation of Arabinogalactan Sponges Prepared by Reductive Amination," Biomaterials 23:4621-31(2002).	
	39	KOBAYASHI H, et al., "Corneal Cell Adhesion and Proliferation on Hydrogel Sheets Bound with Cell-Adhesive Proteins," Current Eye Research, Vol. 10, No. 10, 899-908(October 1991).	
	40	KOBAYASHI H, et al., "Covalent Immobilization of Proteins on to the Surface of Poly (Vinyl Alcohol) Hydrogel," Biomaterials Vol. 12, pages 747-751(October 1991).	
	41	KUO C, et al., "Ionically Crosslinked Alginate Hydrogels as Scaffolds for Tissue Engineering: part 1. Structure, Gelation Rate and Mechanical Properties," Biomaterials 22(6):511-21(2001).	
	42	KUHL P, et al., "Tethered Epidermal Growth Factor as a Paradigm for Growth Factor-Induced Stimulation from the Solid Phase," Nat. Med. 2(9):1022-7(September 1996).	
	43	LANGER R, et al., "Tissue Engineering," Science 260(5110):920-6(May 1993).	
	44	LEE K, et al., "Controlling Mechanical and Swelling Properties of Alginate Hydrogels Independently by Cross-Linker Type and Cross-Linking Density," Macromolecules 33:4291-4294(2000).	
	45	LIM F, et al., "Microencapsulation of Living Cells and Tissues," J. Pharm. Sci. 70(4):351-4(April 1981).	
	46	LOEBSACK A, et al., "In vivo Characterization of a Porous Hydrogel Material for Use as a Tissue Bulking Agent," J. Biomed. Mater. Res. 57(4):575-81(December 2001).	
	47	MAHONEY M et al., "Transplantation of Brain Cells Assembled Around A Programmable Synthetic Microenvironment," Nat. Biotechnol. 19(10):934-9(October 2001).	
	48	MANN B, et al., "Cell Adhesion Peptides Alter Smooth Muscle Cell Adhesion, Proliferation, Migration, and Matrix Protein Synthesis on Modified Surfaces and in Polymer Scaffolds," J. Biomed. Mater. Res. 60(1):86-93(April 2002).	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 5 of 7

Complete if Known

Application Number	10/673,438
Filing Date	September 30, 2003
First Named Inventor	Jon Rowley et al.
Art Unit	1651
Examiner Name	Unassigned
Attorney Docket Number	020187.0239PTUS

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	49	MANN B, et al., "Smooth Muscle Cell Growth in Photopolymerized Hydrogels with Cell Adhesive and Proteolytically Degradable Domains: Synthetic ECM Analogs for Tissue Engineering," Biomaterials 22(22):3045-51(2001).	
	50	MANN B, et al., "Tethered-TGF- β Increases Extracellular Matrix Production of Vascular Smooth Muscle Cells," Biomaterials 22(5):439-44(2001).	
	51	MARLER J, et al., "Soft-Tissue Augmentation with Injectable Alginate and Syngeneic Fibroblasts," Plast. Reconstr. Surg. 105(6):2049-58(May 2000).	
	52	MARTIN I, et al., "Enhanced Cartilage Tissue Engineering by Sequential Exposure of Chondrocytes to FGF-2 during 2D Expansion and BMP-2 during 3D Cultivation," J. Cell. Biochem. 83(1):121-8(2001).	
	53	MASSIA S, et al., "An RGD Spacing of 440 m is Sufficient for Integrin Alpha-V Beta-3 Mediated Fibroblast Spreading and 140 m for Focal Contact and Stress Fiber Formation," J. Cell. Biol. 114:1089-1100(September 1991).	
	54	MASSIA S, et al., "Covalent Surface Immobilization of Arg-Gly-Asp- and Tyr-Ile-Gly-Ser-Arg- Containing Peptides to Obtain Well-Defined Cell-Adhesive Substrates," Anal. Biochem. 187:292-301(June 1990).	
	55	MASSIA S et al., "Human Endothelial Cell Interactions with Surface-Coupled Adhesion Peptides on a Nonadhesive Glass Substrate and Two Polymeric," Biomaterials. J. Biomed. Mater. Res. 25(2):223-42(February 1991).	
	56	MOONEY D, et al., "Extracellular Matrix Controls Tubulin Monomer Levels in Hepatocytes by Regulating Protein Turnover," Mol. Biol. Cell. 5(12):1281-8(December 1994).	
	57	MOONEY D, et al., "Switching From Differentiation to Growth in Hepatocytes: Control by Extracellular Matrix," J. Cell. Physiol. 151(3):497-505(June 1992).	
	58	MOSAHEBI A, et al., "A Novel Use of Alginate Hydrogel as Schwann Cell Matrix," Tissue Eng. 7(5):525-34(2001).	
	59	NIKOLOVSKI J, et al., "Smooth Muscle Cell Adhesion to Tissue Engineering Scaffolds," Biomaterials 21(20):2025-32(2000).	
	60	NOR J, et al., "Engineering And Characterization of Functional Human Microvessels in Immunodeficient Mice," Lab Invest. 81(4):453-63(April 2001).	
	61	NUTTELMAN C, et al., "Attachment of Fibronectin to Poly(Vinyl Alcohol) Hydrogels Promotes NIH3T3 Cell Adhesion, Proliferation, and Migration," J. Biomed. Mater. Res. 57(2):217-23(November 2001).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 6 of 7

Complete if Known

Application Number	10/673,438
Filing Date	September 30, 2003
First Named Inventor	Jon Rowley et al.
Art Unit	1651
Examiner Name	Unassigned
Attorney Docket Number	020187.0239PTUS


NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	62	PALECEK S, et al., "Integrin-Ligand Binding Properties Govern Cell Migration Speed Through Cell-Substratum Adhesiveness," Nature 385(6616):537-40(February 1997).	
	63	PEI, M et al., "Growth Factors for Sequential Cellular De- and Re-differentiation in Tissue Engineering," Biochem. Biophys. Res. Commun. 294(1): 149-54(2002).	
	64	PEPPAS N, "Hydrogels in Medicine and Pharmacy," Vol. 1, CRC Press, 1986.	
	65	PETERS M, et al., "Engineering Vascular Networks in Porous Polymer Matrices," J. Biomed. Mater. Res. 60(4):668-78(June 2002).	
	66	PETRONIS S, et al., "Microstructuring Ceramic Scaffolds for Hepatocyte Cell Culture," Journal of Materials Science: Materials in Medicine 12(6):523-28(June 2001).	
	67	PRESTWICH G, et al., "Controlled Chemical Modification of Hyaluronic Acid: Synthesis, Applications, and Biodegradation of Hydrazide Derivatives," J. Controlled Release. 53, pages 93-103(1998).	
	68	RICHARDSON T, et al., "Polymeric System for Dual Growth Factor Delivery," Nat. Biotechnol. 19(11):1029-34(November 2001).	
	69	PUELACHER W, et al., "Design of Nasoseptal Cartilage Replacements Synthesized from Biodegradable Polymers and Chondrocytes," Biomaterials 15(10):774-78(1994).	
	70	RATNER B., "The Engineering Of Biomaterials Exhibiting Recognition and Specificity," J Mol. Recognit. 9(5-6):617-25(1996).	
	71	ROWLEY J, et al., "Alginate Hydrogels as Synthetic Extracellular Matrix Materials," Biomaterials. 20(1):45-53(1999).	
	72	ROWLEY J, et al. Covalently Modified Alginate. Abstracts of Papers of The American Chemical Society. 213:390-COLL(1997).	
	73	ROWLEY J, et al., "Alginate Type and RGD Density Control Myoblast Phenotype," J. Biomed. Mater. Res. 60(2):217-23(May 2002).	
	74	ROWLEY J, et al., "Biomaterials to Spatially Control Cell Fate," Adv. Mater. 14(12):886-89(2002).	
	75	ROWLEY J., "Controlling Alginate Hydrogel Mechanics," Ph.D. Thesis, Univ. of Michigan. pages 71-109(2001).	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 7 of 7

Complete if Known

Application Number	10/673,438
Filing Date	September 30, 2003
First Named Inventor	Jon Rowley et al.
Art Unit	1651
Examiner Name	Unassigned
Attorney Docket Number	020187.0239PTUS

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	76	SCHMEDLEN R, et al., "Photocrosslinkable Polyvinyl Alcohol Hydrogels that can be Modified with Cell Adhesion Peptides for Use in Tissue Engineering," Biomaterials 23(22):4325-32(2002).	
	77	SHAPIRO L, et al., "Novel Alginate Sponges for Cell Culture and Transplantation," Biomaterials 18(8):583-90(1997).	
	78	SHEA, et al., "DNA Delivery from Polymer Matrices for Tissue Engineering," Nature Biotechnology 17: 551-554 (June 1999).	
	79	SMENTANA K., "Cell Biology of Hydrogels," Biomaterials 14:1046-50(1993).	
	80	STITT D, et al., "Determination of Growth Rate of Microorganisms in Broth from Oxygen-Sensitive Fluorescence Plate Reader Measurements," Biotechniques 32(3):684- 689(March 2002).	
	81	TIMMINS M, et al., "Monitoring the Oxygen Consumption Rates of Cells in Culture," BD The Cell/Line 12(1):8-11(2002).	
	82	VUKICEVIC S, et al., "Differentiation of Canalicular Cell Processes in Bone Cells by Basement Membrane Matrix Components: Regulation by Discrete Domains of Laminin," Cell, 63:437-45(October 1990).	
	83	VUNJAK-NOVAKOVIC G, et al., "Bioreactor Cultivation Conditions Modulate the Composition and Mechanical Properties of Tissue-Engineered Cartilage," J. Orthop. Res. 17(1):130-8(1999).	
	84	WAHLGREN M, et al., "Protein Adsorption to Solid Surfaces," Trends Biotechnol. 9(6):201-8(June 1991).	
	85	WANG N, et al., "Mechanotransduction Across the Cell Surface and Through the Cytoskeleton," Science 260(5111):1124-7(1993).	
	86	WICHTERLE O, et al., "Hydrophilic Gels for Biological Use," Nature 185:117-18(January 1960).	
	87	WODNICKA M, et al., "Novel Fluorescent Technology Platform for High Throughput Cytotoxicity and Proliferation Assays," J. Biomol. Screen, 5(3):141-52(June 2000).	
	88	ZHU H, et al., "Surface Engineering of Poly(DL-Lactic Acid) by Entrapment of Alginate-Amino Acid Derivatives for Promotion of Chondrogenesis," Biomaterials. 23:3141-48(2002).	
	89	ZMORA S, et al., "Tailoring the Pore Architecture in 3-D Alginate Scaffolds by Controlling the Freezing Regime During Fabrication," Biomaterials 23:4087-94(2002).	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450.